Dr. Strosberg on Challenges in the Treatment of Neuroendocrine Tumors

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the challenges associated with treating neuroendocrine tumors (NETs).

Although there are many emerging therapies for NETs, there is little to no information on sequencing. Sequencing may give more information on what works best in the general population, but better predictive factors are needed in such a heterogeneous patient population.

Predictive factors are also needed to help determine which patients will best respond to immunotherapy, as it will probably be a small population, Strosberg says.